
    
      This will be an open-label, Phase 1/2a, multicenter, single-arm, interventional trial that
      will first evaluate the dose limiting toxicity (DLT) of escalating numbers of ultrasound
      beams at constant acoustic pressure using a standard escalation (Phase 1) and then confirm
      the safety and efficacy of BBB opening (Phase 2a expansion).
    
  